Skip to main content
Medical information Clinical review pending

Cytogenetics

CCND1

The CCND1 test is a genetic analysis used in oncology to identify mutations in the CCND1 gene, which can be associated with certain cancers. This information can help guide treatment decisions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Tumor tissue (Paraffin embedded tissue blocks). Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
A Doctor’s prescription is required. This test is generally not applicable for surgery, pregnancy, or individuals planning to travel abroad. Consult your doctor for specific instructions.
Test priceKSh 18,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the CCND1 test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients with specific types of cancer where CCND1 mutations are relevant.
  • ✓Individuals undergoing cancer treatment where genetic information may influence therapy.
  • ✓Patients with a family history suggestive of hereditary cancer syndromes involving CCND1.
  • ✓Assessment of tumor genetic profile for personalized treatment planning.
02

In plain language

What this test helps you understand

Identifies mutations in the CCND1 gene, which can be associated with certain cancers. This information may help guide treatment decisions and personalized medicine approaches.
The CCND1 test is a diagnostic tool used in oncology to evaluate genetic factors related to cancer. It focuses on identifying mutations within the CCND1 gene, which plays a role in cell cycle regulation and can be linked to various types of cancer. Understanding these genetic alterations is important for developing personalized treatment strategies.

This test analyzes tumor tissue samples to detect specific changes in the CCND1 gene. The results provide valuable insights into the genetic makeup of the tumor, assisting healthcare providers in making informed decisions about treatment options and potential therapies.

This test may be considered for individuals with a family history of cancer, those experiencing cancer-related symptoms, or patients currently undergoing cancer treatment who could benefit from genetic information for better management. It is particularly relevant for patients with tumors potentially influenced by genetic factors.

Key benefits of the CCND1 test include supporting personalized treatment planning based on genetic findings, potentially aiding in early detection of cancer risks, and informing decisions about surgical options and therapies.

It is crucial to discuss your test results with your healthcare provider for accurate interpretation and guidance on how the findings may impact your treatment plan.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA Doctor’s prescription is required. This test is generally not applicable for surgery, pregnancy, or individuals planning to travel abroad. Consult your doctor for specific instructions.
SampleTumor tissue (Paraffin embedded tissue blocks). Confirm specific requirements with the laboratory before booking.
MethodologyGenetic analysis of tumor tissue to detect alterations in the CCND1 gene. Confirm specific methodology with the laboratory before booking.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects specific alterations in the CCND1 gene. It does not rule out other genetic factors or types of cancer. Results should be interpreted in the context of the patient's clinical picture.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The CCND1 gene provides instructions for making a protein involved in regulating the cell cycle, which controls cell growth and division. Alterations in this gene can be associated with certain cancers.
This test is typically recommended for cancer patients, particularly those with specific tumor types, to help guide treatment decisions. Your doctor will determine if it's appropriate for you.
The test requires a tumor tissue sample, usually obtained from a biopsy or surgery and preserved in paraffin blocks. Your doctor will arrange for the appropriate sample collection.
Confirm with the laboratory before booking.
Results indicate whether specific alterations in the CCND1 gene were detected. Your doctor will interpret these results in the context of your overall health and cancer diagnosis.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp